
Monika Podhorecka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2135136/publications.pdf Version: 2024-02-01



MONIKA PODHORECKA

#	Article	IF	CITATIONS
1	Metformin - its anti-cancer effects in hematologic malignancies. Oncology Reviews, 2021, 15, 514.	0.8	14
2	Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. Cancer Management and Research, 2021, Volume 13, 1459-1476.	0.9	3
3	Prognostic significance of isochromosome 17q in hematologic malignancies. Oncotarget, 2021, 12, 708-718.	0.8	3
4	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 105-113.	0.2	3
5	<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies –ÂA Narrative Review</p> . Cancer Management and Research, 2020, Volume 12, 2961-2977.	0.9	52
6	Pierwotne chÅ,oniaki nadnerczy jako interdyscyplinarny problem endokrynologiczny i hematologiczny — praktyczne wskazówki w zakresie diagnostyki i leczenia. Hematologia, 2020, 11, 125-165.	0.0	0
7	<p>Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients</p> . Cancer Management and Research, 2019, Volume 11, 5021-5031.	0.9	6
8	Intraventricular treatment of secondary central nervous system lymphoma – Case study and literature overview. Neurologia I Neurochirurgia Polska, 2018, 52, 410-414.	0.6	1
9	Central nervous involvement by chronic lymphocytic leukaemia. Neurologia I Neurochirurgia Polska, 2018, 52, 228-234.	0.6	3
10	Abnormal microRNA expression in the course of hematological malignancies. Cancer Management and Research, 2018, Volume 10, 4267-4277.	0.9	32
11	Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease. Oncotarget, 2018, 9, 19136-19146.	0.8	5
12	Neutropenia in adults – significant diagnostic issue. Pielegniarstwo XXI Wieku, 2018, 17, 37-43.	0.2	0
13	ZespóÅ, hemofagocytowy indukowany terapiÄ hormonalnÄ â€" studium przypadku klinicznego. Acta Haematologica Polonica, 2018, 49, 151-156.	0.1	Ο
14	DNA Damage Response Resulting from Replication Stress Induced by Synchronization of Cells by Inhibitors of DNA Replication: Analysis by Flow Cytometry. Methods in Molecular Biology, 2017, 1524, 107-119.	0.4	8
15	Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. Oncotarget, 2017, 8, 34661-34669.	0.8	28
16	Metformin – its potential anti-cancer and anti-aging effects. Postepy Higieny I Medycyny Doswiadczalnej, 2017, 71, 0-0.	0.1	108
17	Metformina: stary lek w nowej aplikacji. Acta Haematologica Polonica, 2016, 47, 139-145.	0.1	1
18	Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia. Annals of Hematology, 2016, 95, 425-435.	0.8	7

Monika Podhorecka

#	Article	IF	CITATIONS
19	Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 32846-32853.	0.8	44
20	Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?. Current Cancer Drug Targets, 2016, 16, 652-658.	0.8	3
21	Advances in hematology – research that revolutionized patient care. Zdrowie Publiczne, 2015, 125, 32-35.	0.2	Ο
22	The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia. European Journal of Clinical Pharmacology, 2015, 71, 1121-1127.	0.8	2
23	Target Therapy in Hematological Malignances: New Monoclonal Antibodies. International Scholarly Research Notices, 2014, 2014, 1-16.	0.9	6
24	Bullous pyoderma gangrenosum associated with pancytopenia of unknown origin. Postepy Dermatologii I Alergologii, 2014, 4, 272-276.	0.4	6
25	Danazol – możliwości wykorzystania w leczeniu chorób hematologicznych. Acta Haematologica Polonica, 2014, 45, 184-189.	0.1	Ο
26	Deleterious effects of traditional Chinese medicine preparations on the course of psoriasisa case report. Annals of Agricultural and Environmental Medicine, 2013, 20, 816-8.	0.5	4
27	Editorial (Hot Topic: The Importance of Rational Chemotherapy of Chronic Lymphocytic Leukemia). Current Pharmaceutical Design, 2012, 18, 3321-3322.	0.9	Ο
28	Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. Annals of Hematology, 2011, 90, 173-183.	0.8	35
29	Cell Synchronization by Inhibitors of DNA Replication Induces Replication Stress and DNA Damage Response: Analysis by Flow Cytometry. Methods in Molecular Biology, 2011, 761, 85-96.	0.4	33
30	Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Annals of Hematology, 2010, 89, 1115-1124.	0.8	30
31	H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. Journal of Nucleic Acids, 2010, 2010, 1-9.	0.8	393
32	Assessment of Peripheral Blood and Bone Marrow Cells Apoptosis Caused by Purine Analogues in Patients with Chronic Lymphocytic Leukemia in Correlation with Parameters of Disease Progression. Acta Haematologica, 2010, 123, 171-178.	0.7	2
33	Cytometric detection of chromatin relaxation, an early reporter of DNA damage response. Cell Cycle, 2009, 8, 2233-2237.	1.3	22
34	Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures. Leukemia Research, 2009, 33, 997-1000.	0.4	5
35	Intracellular Cytokine Expression by T Cells Differs in ZAP-70-Positive and ZAP-70-Negative Chronic Lymphocytic Leukaemia Patients. Acta Haematologica, 2007, 118, 106-110.	0.7	0
36	Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. European Journal of Clinical Pharmacology, 2006, 62, 325-329.	0.8	12

Monika Podhorecka

#	Article	IF	CITATIONS
37	High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment Blood, 2006, 108, 2108-2108.	0.6	0
38	Clinical Efficacy and Safety of Combined Thalidomide and Fludarabine Therapy in B-Cell Chronic Lymphocytic Leukemia Patients Blood, 2006, 108, 4975-4975.	0.6	0
39	Lovastatin and Thalidomide Have an Synergic Effect on the Rate of Multiple Myeloma Cell Apoptosis in Short Term Cell Cultures Blood, 2005, 106, 5121-5121.	0.6	0
40	Intracellular IFN-Î ³ expression by CD3+/CD8+ cell subset in B-CLL patients correlates with stage of the disease. European Journal of Haematology, 2004, 73, 29-35.	1.1	15
41	ZAP-70 Versus CD38 Expression as the Prognostic Factors in B-Cell Chronic Lymphocytic Leukemia Blood, 2004, 104, 4780-4780.	0.6	0
42	Influence of lovastatin on BCL-2 and BAX expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells. Polish Journal of Pharmacology, 2004, 56, 485-9.	0.3	6
43	T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia—the three-color flow cytometry analysis. Leukemia Research, 2002, 26, 657-660.	0.4	66
44	Short Communication: Expression of Apoptosis Regulating Factors on T Lymphocytes in Multiple Myeloma Patients. Hematology, 2001, 6, 393-397.	0.7	0
45	Assessment of Apoptosis Regulating Factors BCL-2 and Fas Antigens on Malignant and Normal Plasma Cells. Hematology, 2001, 6, 255-260.	0.7	Ο